Advertisement

Current Addiction Reports

, Volume 5, Issue 3, pp 330–335 | Cite as

Major Depression and Sedative-Hypnotic Use Disorder: a Review

  • Lian-Yu Chen
  • Christopher N. Kaufmann
  • Ramin Mojtabai
Dual Diagnosis (T George and A Hassan, Section Editors)
  • 12 Downloads
Part of the following topical collections:
  1. Topical Collection on Dual Diagnosis

Abstract

Purpose of Review

Nonmedical use or addiction of sedative-hypnotics is commonly seen among patients with major depressive disorder (MDD). The aim of this article is to review the prevalence of, the relationship between, and the current treatment of MDD comorbid with sedative-hypnotic use disorder.

Recent Findings

Approximately 3–5% of general population is prescribed sedative-hypnotic medications and prescribing of these agents is more common in women and the elderly. About 2.3% of the US population reported using hypnotics nonmedically, with 0.6% reporting using sedatives nonmedically. Among these nonmedical sedative-hypnotic users, 9.8% met criteria for sedative use disorders. MDD was found to be associated with higher odds of sedative-hypnotics both in adult and adolescent population; however, very few studies examined specifically the prevalence of sedative-hypnotic use disorders in MDD patients. The main motive to misuse or abuse these medications is self-medication of sleep and anxiety problems. In addition, the relationship between MDD and sedative-hypnotic use disorders seems bidirectional. While MDD is a risk factor for the development of sedative-hypnotic use disorder, long-term use of these medications could lead to occurrence of MDD. Thus, it is crucial to offer integrated program that could treat both MDD and sedative-hypnotic use disorder simultaneously.

Summary

Adequate treatment of MDD and earlier identification of sedative-hypnotic use problems are essential for the treatment of MDD with sedative-hypnotic use disorder. A more integrated treatment program that fulfills the need of patients with both mental and addiction problems should be developed and expanded.

Keywords

Dual diagnosis Sedative-hypnotic use disorder Major depressive disorder 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Strain EC. Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clin J Pain. 2002;18(4 Suppl):S14–27.CrossRefPubMedGoogle Scholar
  2. 2.
    Brady KT, Sinha R. Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress. Am J Psychiatry. 2005;162(8):1483–93.CrossRefPubMedGoogle Scholar
  3. 3.
    Harris KM, Edlund MJ. Use of mental health care and substance abuse treatment among adults with co-occurring disorders. Psychiatr Serv. 2005;56(8):954–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Buckley PF. Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. J Clin Psychiatry. 2006;67(Suppl 7):5–9.PubMedGoogle Scholar
  5. 5.
    Buckley PF, Brown ES. Prevalence and consequences of dual diagnosis. J Clin Psychiatry. 2006;67(7):e01.CrossRefPubMedGoogle Scholar
  6. 6.
    Martins SS, Fenton MC, Keyes KM, Blanco C, Zhu H, Storr CL. Mood and anxiety disorders and their association with non-medical prescription opioid use and prescription opioid-use disorder: longitudinal evidence from the National Epidemiologic Study on Alcohol and Related Conditions. Psychol Med. 2012;42(6):1261–72.CrossRefPubMedGoogle Scholar
  7. 7.
    Chen LY, Crum RM, Martins SS, Kaufmann CN, Strain EC, Mojtabai R. Service use and barriers to mental health care among adults with major depression and comorbid substance dependence. Psychiatr Serv. 2013;64(9):863–70.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Tsuno N, Besset A, Ritchie K. Sleep and depression. J Clin Psychiatry. 2005;66(10):1254–69.CrossRefPubMedGoogle Scholar
  9. 9.
    Soehner AM, Kaplan KA, Harvey AG. Prevalence and clinical correlates of co-occurring insomnia and hypersomnia symptoms in depression. J Affect Disord. 2014;167:93–7.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kessler RC, Sampson NA, Berglund P, Gruber MJ, Al-Hamzawi A, Andrade L, et al. Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epidemiol Psychiatr Sci. 2015;24(3):210–26.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Jacobson NC, Newman MG. Anxiety and depression as bidirectional risk factors for one another: a meta-analysis of longitudinal studies. Psychol Bull. 2017;143(11):1155–200.CrossRefPubMedGoogle Scholar
  12. 12.
    Bao YP, Han Y, Ma J, Wang RJ, Shi L, Wang TY, et al. Cooccurrence and bidirectional prediction of sleep disturbances and depression in older adults: meta-analysis and systematic review. Neurosci Biobehav Rev. 2017;75:257–73.CrossRefPubMedGoogle Scholar
  13. 13.
    Baglioni C, Battagliese G, Feige B, Spiegelhalder K, Nissen C, Voderholzer U, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011;135(1–3):10–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Jansson-Frojmark M, Lindblom K. A bidirectional relationship between anxiety and depression, and insomnia? A prospective study in the general population. J Psychosom Res. 2008;64(4):443–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Staner L. Comorbidity of insomnia and depression. Sleep Med Rev. 2010;14(1):35–46.CrossRefPubMedGoogle Scholar
  16. 16.
    •• Soyka M. Treatment of benzodiazepine dependence. N Engl J Med. 2017;376(24):2399–400. This is a very comprehensive review on the clinical manifestation and management of benzodiazepine dependence. PubMedGoogle Scholar
  17. 17.
    Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust Prescr. 2015;38(5):152–5.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Victorri-Vigneau C, Dailly E, Veyrac G, Jolliet P. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol. 2007;64(2):198–209.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013. Am J Public Health. 2016;106(4):686–8.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Bertisch SM, Herzig SJ, Winkelman JW, Buettner C. National use of prescription medications for insomnia: NHANES 1999-2010. Sleep. 2014;37(2):343–9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Chong Y, Fryer CD, Gu Q. Prescription sleep aid use among adults: United States, 2005-2010. NCHS Data Brief. 2013;127:1–8.Google Scholar
  22. 22.
    Ford ES, Wheaton AG, Cunningham TJ, Giles WH, Chapman DP, Croft JB. Trends in outpatient visits for insomnia, sleep apnea, and prescriptions for sleep medications among US adults: findings from the National Ambulatory Medical Care survey 1999-2010. Sleep. 2014;37(8):1283–93.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Kaufmann CN, Spira AP, Alexander GC, Rutkow L, Mojtabai R. Trends in prescribing of sedative-hypnotic medications in the USA: 1993-2010. Pharmacoepidemiol Drug Saf. 2016;25(6):637–45.CrossRefPubMedGoogle Scholar
  24. 24.
    Kaufmann CN, Spira AP, Depp CA, Mojtabai R. Continuing versus new prescriptions for sedative-hypnotic medications: United States, 2005-2012. Am J Public Health. 2016;106(11):2019–25.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kaufmann CN, Spira AP, Depp CA, Mojtabai R. Long-term use of benzodiazepines and nonbenzodiazepine hypnotics, 1999-2014. Psychiatr Serv. 2018;69(2):235–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Karlsson B, Johnell K, Sigstrom R, Sjoberg L, Fratiglioni L. Depression and depression treatment in a population-based study of individuals over 60 years old without dementia. Am J Geriatr Psychiatry. 2016;24(8):615–23.CrossRefPubMedGoogle Scholar
  27. 27.
    Steffens DC, Skoog I, Norton MC, Hart AD, Tschanz JT, Plassman BL, et al. Prevalence of depression and its treatment in an elderly population: the Cache County study. Arch Gen Psychiatry. 2000;57(6):601–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Brandt J, Leong C. Benzodiazepines and Z-drugs: an updated review of major adverse outcomes reported on in epidemiologic research: Drugs R D 2017;17(4):493–507.  https://doi.org/10.1007/s40268-017-0207-7.
  29. 29.
    Herings RM, Stricker BH, de Boer A, Bakker A, Sturmans F. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med 1995;155(16):1801–1807.Google Scholar
  30. 30.
    Mendelson WB. The use of sedative/hypnotic medication and its correlation with falling down in the hospital. Sleep. 1996;19(9):698–701.PubMedGoogle Scholar
  31. 31.
    Mets MA, Volkerts ER, Olivier B, Verster JC. Effect of hypnotic drugs on body balance and standing steadiness. Sleep Med Rev. 2010;14(4):259–67.CrossRefPubMedGoogle Scholar
  32. 32.
    Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Zolpidem use and hip fractures in older people. J Am Geriatr Soc. 2001;49(12):1685–90.CrossRefPubMedGoogle Scholar
  33. 33.
    • Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA psychiatry. 2015;72(2):136–42. This study described the pattern of benzodiazepine prescription focusing on patient age and duration of use and found long-term benzodiazepine use was particularly pronounced in the elderly. CrossRefPubMedGoogle Scholar
  34. 34.
    Zhong G, Wang Y, Zhang Y, Guo JJ, Zhao Y. Smoking is associated with an increased risk of dementia: a meta-analysis of prospective cohort studies with investigation of potential effect modifiers. PLoS One. 2015;10(3):e0118333.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Billioti de Gage S, Moride Y, Ducruet T, Kurth T, Verdoux H, Tournier M, et al. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ. 2014;349.Google Scholar
  36. 36.
    Chen PL, Lee WJ, Sun WZ, Oyang YJ, Fuh JL. Risk of dementia in patients with insomnia and long-term use of hypnotics: a population-based retrospective cohort study. PLoS One. 2012;7(11):7.Google Scholar
  37. 37.
    Gallacher J, Elwood P, Pickering J, Bayer A, Fish M, Ben-Shlomo Y. Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Health. 2012;66(10):869–73.CrossRefPubMedGoogle Scholar
  38. 38.
    Lagnaoui R, Begaud B, Moore N, Chaslerie A, Fourrier A, Letenneur L, et al. Benzodiazepine use and risk of dementia: a nested case-control study. J Clin Epidemiol. 2002;55(3):314–8.CrossRefPubMedGoogle Scholar
  39. 39.
    McCall WV, Benca RM, Rosenquist PB, Riley MA, McCloud L, Newman JC, et al. Hypnotic medications and suicide: risk, mechanisms, mitigation, and the FDA. Am J Psychiatry. 2017;174(1):18–25.CrossRefPubMedGoogle Scholar
  40. 40.
    Sun Y, Lin CC, Lu CJ, Hsu CY, Kao CH. Association between zolpidem and suicide: a nationwide population-based case-control study. Mayo Clin Proc. 2016;91(3):308–15.CrossRefPubMedGoogle Scholar
  41. 41.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.CrossRefGoogle Scholar
  42. 42.
    Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA. 1989;262(11):1479–84.CrossRefPubMedGoogle Scholar
  43. 43.
    Hirschfeld RM. The comorbidity of major depression and anxiety disorders: recognition and management in primary care. Prim Care Companion J Clin Psychiatry. 2001;3(6):244–54.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    •• Hughes A, Williams MR, Lipari RN, Bose J, Copello EAP, Kroutil LA. Prescription drug use and misuse in the United States: results from the 2015 National Survey on Drug Use and Health. NSDUH Data Review. 2016; This NSDUH report offers a general picture of the scope of prescription drug misuse or addiction problem in the USA. Higher odds of mental disorders and behavior problems are found to be associated with misuse of prescription sedative-hypnotics. Google Scholar
  45. 45.
    Becker WC, Fiellin DA, Desai RA. Non-medical use, abuse and dependence on sedatives and tranquilizers among U.S. adults: psychiatric and socio-demographic correlates. Drug Alcohol Depend. 2007;90(2–3):280–7.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    •• Young AM, Glover N, Havens JR. Nonmedical use of prescription medications among adolescents in the United States: a systematic review. J Adolesc Health. 2012;51(1):6–17. This study offers evidence that misuse or addiction of sedative-hypnotic medications is associated with mental or behavioral problems in adolescent population. CrossRefPubMedGoogle Scholar
  47. 47.
    Kokkevi A, Fotiou A, Arapaki A, Richardson C. Prevalence, patterns, and correlates of tranquilizer and sedative use among European adolescents. The Journal of adolescent health : official publication of the Society for Adolescent Medicine. 2008;43(6):584–92.CrossRefGoogle Scholar
  48. 48.
    Woods JH, Katz JL, Winger G. Use and abuse of benzodiazepines. Issues relevant to prescribing. Jama. 1988;260(23):3476–80.CrossRefPubMedGoogle Scholar
  49. 49.
    Hallstrom C, Lader M. Benzodiazepine withdrawal phenomena. Int Pharmacopsychiatry. 1981;16(4):235–44.CrossRefPubMedGoogle Scholar
  50. 50.
    Ashton H. The diagnosis and management of benzodiazepine dependence. Current opinion in psychiatry. 2005;18(3):249–55.CrossRefPubMedGoogle Scholar
  51. 51.
    O'Connor KP, Marchand A, Belanger L, Mainguy N, Landry P, Savard P, et al. Psychological distress and adaptational problems associated with benzodiazepine withdrawal and outcome: a replication. Addict Behav. 2004;29(3):583–93.CrossRefPubMedGoogle Scholar
  52. 52.
    Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006;67(2):247–57.CrossRefPubMedGoogle Scholar
  53. 53.
    Fenton MC, Keyes KM, Martins SS, Hasin DS. The role of a prescription in anxiety medication use, abuse, and dependence. Am J Psychiatry. 2010;167(10):1247–53.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Kan CC, Hilberink SR, Breteler MH. Determination of the main risk factors for benzodiazepine dependence using a multivariate and multidimensional approach. Compr Psychiatry. 2004;45(2):88–94.CrossRefPubMedGoogle Scholar
  55. 55.
    Ford JA, McCutcheon J. The misuse of Ambien among adolescents: prevalence and correlates in a national sample. Addict Behav. 2012;37(12):1389–94.CrossRefPubMedGoogle Scholar
  56. 56.
    Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264(19):2511–8.CrossRefPubMedGoogle Scholar
  57. 57.
    Kessler RC, Nelson CB, McGonagle KA, Edlund MJ, Frank RG, Leaf PJ. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. The American journal of orthopsychiatry. 1996;66(1):17–31.CrossRefPubMedGoogle Scholar
  58. 58.
    Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61(8):807–16.CrossRefPubMedGoogle Scholar
  59. 59.
    Kessler RC. The epidemiology of dual diagnosis. Biol Psychiatry. 2004;56(10):730–7.CrossRefPubMedGoogle Scholar
  60. 60.
    Dell'osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry. 2013;28(1):7–20.CrossRefPubMedGoogle Scholar
  61. 61.
    Center for Behavioral Health Statistics and Quality. Key substance use and mental health indicators in the United States: results from the 2015 National Survey on Drug Use and Health (HHS Publication No.SMA 16–4984, NSDUH Series H-51). 2016. Retrieved from http://www.samhsa.gov/data/.
  62. 62.
    Nattala P, Murthy P, Thennarasu K, Cottler LB. Nonmedical use of sedatives in urban Bengaluru. Indian J Psychiatry. 2014;56(3):246–52.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Brower KJ, Perron BE. Sleep disturbance as a universal risk factor for relapse in addictions to psychoactive substances. Med Hypotheses. 2010;74(5):928–33.CrossRefPubMedGoogle Scholar
  64. 64.
    Kripke DF. Greater incidence of depression with hypnotic use than with placebo. BMC psychiatry. 2007;7:42.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Boden JM, Fergusson DM. Alcohol and depression. Addiction. 2011;106(5):906–14.CrossRefPubMedGoogle Scholar
  66. 66.
    Grant BF, Harford TC. Concurrent and simultaneous use of alcohol with sedatives and with tranquilizers: results of a national survey. J Subst Abus. 1990;2(1):1–14.CrossRefGoogle Scholar
  67. 67.
    Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 2004;291(15):1887–96.CrossRefPubMedGoogle Scholar
  68. 68.
    Cornelius JR, Bukstein OG, Wood DS, Kirisci L, Douaihy A, Clark DB. Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder. Addict Behav. 2009;34(10):905–9.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Jaffee WB, Griffin ML, Gallop R, Meade CS, Graff F, Bender RE, et al. Depression precipitated by alcohol use in patients with co-occurring bipolar and substance use disorders. The Journal of clinical psychiatry. 2009;70(2):171–6.CrossRefPubMedGoogle Scholar
  70. 70.
    Department of health (England). Drug misuse and dependence: UK guidelines on clinical management. London; 2007.Google Scholar
  71. 71.
    Chen LY, Strain EC, Crum RM, Mojtabai R. Gender differences in substance abuse treatment and barriers to care among persons with substance use disorders with and without comorbid major depression. J Addict Med. 2013;7(5):325–34.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Mojtabai R, Chen LY, Kaufmann CN, Crum RM. Comparing barriers to mental health treatment and substance use disorder treatment among individuals with comorbid major depression and substance use disorders. J Subst Abus Treat. 2014;46(2):268–73.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Lian-Yu Chen
    • 1
    • 2
  • Christopher N. Kaufmann
    • 3
    • 4
  • Ramin Mojtabai
    • 5
    • 6
  1. 1.Department of Addiction Psychiatry, Taipei City Psychiatric CenterTaipei City HospitalTaipei CityTaiwan
  2. 2.Institute of Epidemiology and Preventive MedicineNational Taiwan UniversityTaipei CityTaiwan
  3. 3.Sam and Rose Stein Institute for Research on AgingUniversity of California San DiegoLa JollaUSA
  4. 4.Department of PsychiatryUniversity of California San DiegoLa JollaUSA
  5. 5.Department of Mental HealthJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA
  6. 6.Department of Psychiatry and Behavioral SciencesJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations